Core Viewpoint - The arbitration progress regarding the exclusive agency rights for "AestheFill" between Aimeike and *ST Suwu has led to significant market reactions, with Aimeike's stock declining and *ST Suwu's stock increasing on the same day [1][2]. Group 1: Arbitration Details - The Shenzhen International Arbitration Court ruled that Aimeike's subsidiary, Regen Biotech, cannot sell "AestheFill" in mainland China and must recognize Datou Medical as the exclusive distributor [1][3]. - Datou Medical's request for additional temporary measures, including the revocation of the exclusive authorization for Lizhen (Xiamen) Medical Technology Co., Ltd., was not granted [2][6]. - The emergency arbitrator confirmed that Datou Medical remains the undisputed exclusive distributor of "AestheFill" in mainland China until a final arbitration decision is made [3][5]. Group 2: Financial Impact - *ST Suwu reported a 27.08% year-on-year decline in revenue for the first half of the year, totaling 636 million yuan, with a net loss of approximately 44.42 million yuan, a 281.63% decrease [7]. - Aimeike's revenue for the same period was 1.299 billion yuan, down 21.59% year-on-year, with a net profit of 789 million yuan, reflecting a 29.57% decline [7]. Group 3: Future Implications - The ongoing arbitration will significantly impact both companies' strategies and developments in the medical aesthetics market, with the arbitration court set to form a tribunal for further proceedings [8].